You are here

Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Invasive Candidiasis, Candidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Acute-care inpatients;

- Aged 18 years or older;

- At least one dose of echinocandin therapy during the hospitalization;

- Primary or secondary ICD-9 discharge diagnosis of invasive candidiasis / candidemia.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

-

- No recorded echinocandin therapy during hospitalization;

- Acetaminophen hepatotoxicity;

- Pre-existing autoimmune hepatitis;

- Autoimmune/metabolic liver disease;

- Primary biliary cirrhosis;

- Primary sclerosing cholangitis and orthotopic liver transplantation.

NCT01213823
Pfizer
Terminated
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Candidemia, Peritonitis) Other Forms of Candida Infections(Intra-abdominal Abscess
NCT00802854
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now